Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Myelodysplastic Syndromes 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 116fludarabine phosphate 101Busulfan 83Tacrolimus 75fludarabine 73Mycophenolic Acid 71Whole-Body Irradiation 65Peripheral Blood Stem Cell Transplantation 59Antilymphocyte Serum 58Cyclosporine 53Azacitidine 53Melphalan 50Cytarabine 47Filgrastim 43Methotrexate 41Granulocyte Colony-Stimulating Factor 34Decitabine 33Radiotherapy 28Thiotepa 27Cord Blood Stem Cell Transplantation 27thymoglobulin 26Stem Cell Transplantation 26Clofarabine 22Methylprednisolone 20Sirolimus 19Alemtuzumab 16venetoclax 15Specimen Handling 14sargramostim 13Etoposide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myelodysplastic Syndromes × lirilumab × Clear all
NCT02599649 2020-01-14

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

M.D. Anderson Cancer Center

Phase 2 Terminated
10 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡